Cas:1131587-49-9 Ethyl 5-iodo-2,4-dimethoxybenzoate manufacturer & supplier

Chemical Name:Ethyl 5-iodo-2,4-dimethoxybenzoate

CAS.NO:1131587-49-9

Synonyms:ethyl 5-iodanyl-2,4-dimethoxy-benzoate

Molecular Formula:C₁₁H₁₃IO₄

Molecular Weight:336.12300

HS Code:

Physical and Chemical Properties:

Melting point:N/A

Boiling point:N/A

Density:N/A

Index of Refraction:

PSA:44.76000

Exact Mass:335.98600

LogP:2.48510

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like ethyl 5-iodanyl-2,4-dimethoxy-benzoate chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,ethyl 5-iodanyl-2,4-dimethoxy-benzoate physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,ethyl 5-iodanyl-2,4-dimethoxy-benzoate Use and application,ethyl 5-iodanyl-2,4-dimethoxy-benzoate technical grade,usp/ep/jp grade.

Related News: The technology supports breakthroughs in medical research and is widely used by major global pharmaceutical companies to advance drug discovery & development and provide data to support regulatory submissions. Ethyl 5-iodo-2,4-dimethoxybenzoate manufacturer Profitability continued to improve. The company’s comprehensive gross profit margin for the first three quarters was 36.06%, a year-on-year increase of 3.44 percentage points. Since this year, the company’s profitability has remained at a relatively high level. On the one hand, due to the decline in the trading business with lower profitability, the proportion has declined. Ethyl 5-iodo-2,4-dimethoxybenzoate supplier Among them, Zhejiang pharmaceutical companies accounted for 4 of the world’s top ten API manufacturers. Ethyl 5-iodo-2,4-dimethoxybenzoate vendor Like Altasciences, Alira has also placed an emphasis on the preclinical setting in recent months with its March hire of Nikole Siegmund as vice president of preclinical development. Ethyl 5-iodo-2,4-dimethoxybenzoate factory The move follows a Class I recall, the FDA’s most serious, launched by Innova in late April amid “significant concerns” about the test’s accuracy—and alongside an official warning letter delivered to the company this week.